Latest News and Press Releases
Want to stay updated on the latest news?
-
New York, USA, Jan. 08, 2024 (GLOBE NEWSWIRE) -- HDAC Inhibitor Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight ...
-
New York, USA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Hearing Screening and Diagnostic Devices Global Market to Observe Stunning Growth at a CAGR of ~7% by 2028 | DelveInsight The hearing screening and...
-
New York, USA, Jan. 03, 2024 (GLOBE NEWSWIRE) -- STAT Inhibitors Clinical Trial Analysis: DelveInsight Evaluates a Robust Pipeline as 22+ Influential Pharma Players to Set Foot in the Domain The...
-
New York, USA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Biopharmaceuticals Global Market is Expected to Surpass 700 Billion Mark by 2028, Assesses DelveInsight The demand for biopharmaceuticals is...
-
New York, USA, Jan. 01, 2024 (GLOBE NEWSWIRE) -- Propulsion of Small Lymphocytic Lymphoma Clinical Trial Pipeline as Novel and Extensive 80+ Therapies Likely to Enter in the Domain | DelveInsight ...
-
New York, USA, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Autoimmune Diseases Diagnostics Global Market to Surpass 6 Billion Mark by 2028 | DelveInsight The increasing prevalence of autoimmune disorders,...
-
New York, USA, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Digital Therapeutics Global Market to Observe Stunning Growth at a CAGR of ~28% by 2028 | DelveInsight Digital therapeutics present a prospect to...
-
New York, USA, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Pet Food Ingredients Global Market is Projected to Boost CAGR of ~6% by 2028 | DelveInsight The pet food ingredients market is experiencing...
-
New York, USA, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Prebiotics Ingredients Global Market to Observe Impressive Growth at a CAGR of ~10% by 2028 | DelveInsight The prebiotic ingredients market is...
-
New York, USA, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Tuberculosis Diagnostics Global Market Size and Share to Rise at a CAGR of ~5% by 2028 | DelveInsight The rising incidence of tuberculosis and...